glp-1 drug makers Drugs from the Gray Market A Guide to GLPs-1s for

Understanding your policy, exploring compounded alternatives, and considering genetic factors in peptide sensitivity may help guide treatment decisions with your provider

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

60 capsules per bottle (30-day supply)

The use of branded ingredients allows private label partners to leverage established research narratives, ingredient storytelling, and clinical positioning strategies in their marketing materials

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential use in treating alcohol use disorder.